Ypsomed Group

Ypsomed Group develops and manufactures innovative injection and infusion systems for self-medication, serving as a key partner to pharmaceutical companies. The company specializes in advanced drug delivery solutions such as pens, autoinjectors, and wearable devices, enabling the subcutaneous self-administration of various liquid medications. Its technical approach emphasizes modular platforms, ensuring validated, scalable, and patient-centric designs ready for clinical and commercial deployment.

Ypsomed was established in 2003 by Willy Michel, emerging from the dissolution of the Disetronic Group, which he co-founded with his brother Peter Michel in 1984. The formation of Ypsomed solidified a focus on specialized drug delivery systems, leveraging decades of experience in medical technology. This strategic evolution allowed the company to dedicate its efforts to advancing self-injection solutions.

The company's products are utilized by global pharmaceutical partners, ultimately benefiting patients who rely on convenient and reliable self-care therapeutics. Ypsomed's overarching vision is to expand access to self-medication and medical care, thereby enhancing patients' quality of life. It consistently strives to deliver innovative, user-friendly, and dependable self-care products, contributing significantly to therapeutic success and patient autonomy in managing their health.